Edition:
United States

OncoMed Pharmaceuticals Inc (OMED.OQ)

OMED.OQ on NASDAQ Stock Exchange Global Select Market

8.73USD
17 Feb 2017
Change (% chg)

$0.06 (+0.69%)
Prev Close
$8.67
Open
$8.66
Day's High
$8.81
Day's Low
$8.48
Volume
52,447
Avg. Vol
58,443
52-wk High
$15.48
52-wk Low
$7.41

Select another date:

Fri, Jan 20 2017

BRIEF-OncoMed initiates enrollment of phase 1B clinical trial of Brontictuzumab

* OncoMed initiates enrollment of phase 1B clinical trial of Brontictuzumab for the treatment of metastatic colorectal cancer patients Source text for Eikon: Further company coverage:

BRIEF-Oncomed Pharmaceuticals reports Q3 financial results

* "We expect to file inds for two immuno-oncology programs in late 2016 though first half of 2017"

BRIEF-Oncomed Pharmaceuticals provides topline data from phase 2 trial on Tarextumab

* Topline data from phase 2 trial on Tarextumab in small cell lung cancer expected to be reported at end of 2016 or in early 2017 Source text for Eikon: Further company coverage:

BRIEF-BVF Inc reports 4.9 pct passive stake in Oncomed Pharmaceuticals - SEC filing

* BVF Inc reports 4.9 pct passive stake in Oncomed Pharmaceuticals as of Aug. 18, 2016 - SEC filing Source text (http://bit.ly/2bVM8Sx) Further company coverage:

BRIEF-Celgene reports 8.1 pct passive stake in Oncomed Pharmaceuticals

* Celgene Corporation reports 8.1 pct passive stake in Oncomed Pharmaceuticals Inc as of August 23, 2016 - SEC filing Source text: (http://bit.ly/2bBcQ6P) Further company coverage:

Select another date:

More From Around the Web